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Transplantation of allogeneic organs has proven to be an effective therapeutic for a large variety of disease states, but the chronic
immunosuppression that is required for organ allograft survival increases the risk for infection and neoplasia and has direct organ
toxicity. The establishment of transplantation tolerance, which obviates the need for chronic immunosuppression, is the ultimate
goal in the field of transplantation. Many experimental approaches have been developed in animal models that permit long-term
allograft survival in the absence of chronic immunosuppression. These approaches function by inducing peripheral or central
tolerance to the allograft. Emerging as some of the most promising approaches for the induction of tolerance are protocols based
on costimulation blockade. However, as these protocols move into the clinic, there is recognition that little is known as to their
safety and efficacy when confronted with environmental perturbants such as virus infection. In animal models, it has been reported
that virus infection can prevent the induction of tolerance by costimulation blockade and, in at least one experimental protocol,
can lead to significant morbidity and mortality. In this review, we discuss how viruses modulate the induction and maintenance
of transplantation tolerance.
Copyright © 2008 David M. Miller et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Organ transplantation in the clinic became a reality in 1954
when Merrill, Murray, and Harrison performed the first
successful human vascular organ graft, a kidney transplant
[1, 2]. However, the donor and recipient were monozygotic
twins, obviating the need for immunosuppression for organ
graft survival. With the development of immunosuppressive
regimens, the same group 5 years later performed the
first kidney allograft transplantation between unrelated
individuals; that graft survived for 20 years [3]. Although
successful graft survival was achieved, it rapidly became
clear that all immunosuppressive drugs, even the newer
generations of immunosuppressive regimens, are toxic [4, 5].
Immunosuppressive drugs are also known to increase the
risk of infection and neoplasia [6, 7], and their associated
side effects often lead to patient noncompliance [8]. Since
most patients eventually reject transplanted allografts either
acutely or through a process of chronic rejection [9–11],
these deleterious side effects make organ transplantation a
therapy in which the risk/benefit ratio must be carefully
weighed.
To overcome issues associated with chronic immuno-
suppression, investigators have focused on approaches that
lead to the induction of tolerance to transplanted organ
allografts [12]. Operationally, transplantation tolerance is
defined as the survival of a donor allogeneic graft in
the absence of immunosuppression. Most transplantation
tolerance induction protocols take advantage of informa-
tion resulting from studies on the natural mechanisms
by which the immune system prevents self-reactivity and
autoimmune disease. Two major forms of natural tolerance
have been identified: central tolerance and peripheral toler-
ance.
2. CENTRAL TRANSPLANTATION TOLERANCE
In 1953, Peter Medawar et al. obtained the first experimental
evidence that the establishment of allogeneic hematopoietic
chimerism leads to the induction of central tolerance
and permits permanent acceptance of skin allografts [13].
Inspired by the work done in freemartin cattle by Owen in
1945 [14] and the clonal selection theory subsequently pro-
posed by Burnet and Fenner [15], Medawar demonstrated
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in mice that the transfer of allogeneic hematopoietic cells in
utero could induce tolerance to skin transplanted from the
original donor later in life [13].
Medawar’s observation led Main and Prehn to experi-
mentally induce hematopoietic chimerism by treating mice
with whole-body irradiation (WBI) and allogeneic bone
marrow cells, followed by transplantation with donor-strain-
matched skin allografts [16]. This protocol successfully
induced tolerance to skin allografts, conclusively linking the
establishment of hematopoietic chimerism with subsequent
allograft survival. However, despite the long-term survival
of skin allografts on mice treated with WBI and allogeneic
bone marrow, animals eventually develop lethal graft-versus-
host disease (GVHD), a reaction where passenger leukocytes
in the donor bone marrow or graft mount an immune
response against the host. Therefore, modern conditioning
protocols to induce central tolerance have been designed
to address the common objectives of (1) establishing
hematopoietic chimerism using a relatively benign precon-
ditioning protocol that (2) prevents the development of
GVHD.
Despite these common objectives, modern conditioning
regimens can differ quite significantly in their methodology.
In preclinical models of hematopoietic chimerism, condi-
tioning regimens span the spectrum from myeloablative pro-
tocols, which often entail lethal irradiation and subsequent
stem cell rescue, to noncytoreductive treatments that do
not require irradiation, for example, costimulation blockade
[17–19]. Between these two extremes are protocols that
significantly weaken the recipient’s immune system through
selective antibody-mediated elimination of specific immune
populations (e.g., CD4+ and CD8+ T cells) coupled with
targeted irradiation (e.g., thymic irradiation) [20]. These
latter protocols are often considered nonmyeloablative. In
clinical trials, successful nonmyeloablative approaches have
recently been described [21, 22]. Stable renal allograft
function in recipients for as long as five years after complete
withdrawal of immunosuppressive drugs was observed in
recipients in which hematopoietic chimerism was established
[21, 22]. These reports document that in humans, as
in rodents, establishment of hematopoietic chimerism is
a robust approach for the development of central toler-
ance and the permanent survival of donor-specific allo-
grafts.
3. PERIPHERAL TRANSPLANTATION TOLERANCE
The second major form of tolerance is peripheral tolerance.
Different from central tolerance in which hematopoietic
chimerism leads to the clonal deletion of antigen-specific
cells during development, peripheral tolerance targets pre-
existing cells that have already been generated. To induce
tolerance in this population, fundamental insights into how
naive antigen-specific T cells become activated have led to
protocols designed to prevent this process. Naive T cell
activation is initiated by the interaction of the antigen-
specific T cell receptor (TCR) with a peptide presented by
the MHC. This interaction conveys specificity leading to
the activation of only antigen-specific T cells. This signal
is often termed as “signal 1” (Figure 1). Following TCR-
peptide/MHC ligation, a T cell then receives a number of
costimulatory signals [23–25]. A key costimulatory signal
in this pathway that permits the activated naive T cells
to become functional effector/memory T cells is provided
by CD28-CD80/86 interaction [26], which has often been
referred to as “signal 2.” In early studies, it was shown
in vitro that T cells that receive signals through their
TCR in the absence of engagement of the CD28-CD80/86
costimulation pathway became nonresponsive, a state of T
cell nonresponsiveness often referred to as anergy [12, 27].
Following induction of signal 2, cytokines are produced that
impart the final signal for T cell activation, and this is termed
as “signal 3” [24, 28, 29]. Although these three critical signals
are required for the full activation of T cells, additional
signals such as those derived from CD40-CD154 interaction
can have potent effects on the activation of naive T cells
(Figure 1).
The existence of a comparable in vivo state of T cell
nonresponsiveness has been debated for years until it was
independently shown to exist by Ohashi et al. [30] and
Oldstone et al. [31] using two very similar experimental
systems. These investigators generated double-transgenic
mice that expressed (1) lymphocytic choriomeningitis virus
(LCMV) glycoprotein (GP) [30] or nucleoprotein (NP) [31]
under the control of the rat insulin promoter, and (2) a
transgenic TCR that recognizes a peptide from the transgenic
LCMV protein. In unmanipulated mice, the transgenic T
cells migrate from the thymus into the peripheral tissues
and encounter their cognate antigen, but they remain non-
responsive to islets expressing GP or NP. However, LCMV
infection reverses this state of nonresponsiveness, leading
to a diabetic phenotype resulting from the destruction of
pancreatic islets expressing the transgenic protein [30, 31].
These data support a mechanism where the LCMV-reactive
T cells in naive mice encounter antigen in the absence of
costimulation and become nonresponsive (tolerant), and
further show that environmental perturbation can break this
nonresponsive state. This model serves as the conceptual
basis for the induction of peripheral transplantation tol-
erance, where the in vivo disruption of the costimulatory
process—referred to as costimulation blockade—leads to
the induction of tolerance in an antigen-specific manner
[12].
Costimulation blockade therapies can target several
different steps in the process of T cell activation. However, the
CD40-CD154 pathway linking signal 1 to signal 2 has been
identified to be a critical step in the activation of naive T cells.
Anti-CD154 mAb blocks the interaction between CD154 on
the T cell and CD40 on the APC [32, 33], and prevents the
differentiation between naive T cells and effector/memory T
cells [33] (Figure 1).
In peripheral tolerance induction protocols, anti-CD154
monotherapy significantly improves islet [34] and cardiac
[35] allograft survival in mice and islet allograft survival
in nonhuman primates [36–39]. In combination with a
donor-specific transfusion (DST), anti-CD154 monoclonal
antibody (mAb) induces permanent islet [34] and prolonged
skin [40] allograft survival in mice. DST provides selective
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Figure 1: Costimulation blockade. Activation of a T cell involves a series of interactive steps with an APC. The first signal imparts antigen
specificity and commences when the TCR engages the antigen/MHC complex presented by the APC. This signal is commonly referred to
as “signal 1.” In subsequent steps, the T cell receives a number of costimulatory signals, including those following interaction of CD154
on T cells with CD40 on APCs, which matures the APC to upregulate expression of CD80/86. The interaction of CD28 with CD80/86
is termed as “signal 2” and activates APCs to secrete cytokines, which provide the final activation signals to the T cell; this step is
commonly referred to as “signal 3.” Protocols based on costimulation blockade can prevent T cell activation by targeting steps in the T cell
activation cascade. Anti-CD154 mAb blocks the interaction between CD154 and CD40, and prevents the APC from upregulating CD80/86,
blocking full APC activation. This prevents the secretion of proinflammatory cytokines, thus depriving the T cell of signal 3. As a result
of costimulation blockade, the T cell does not develop an activated phenotype, and consequently becomes nonresponsive (tolerant) to
allogeneic antigens.
activation of the alloantigen-specific T cells, and we have
shown that the subsequent blockade of costimulation by
anti-CD154 mAb leads to selective depletion of only the
specific alloantigen-reactive CD8+ T cells [41, 42]. Another
reagent, CTLA4-Ig, binds to the costimulatory molecules
CD80/86 on the APC. This blocks its interaction with CD28
on the T cell, preventing signal 2. CTLA4-Ig monotherapy
induces the survival of xenogeneic islets [43] and allogeneic
cardiac grafts [44]. Not surprisingly, the combination of
anti-CD154 mAb and CTLA4-Ig has shown great potential
in prolonging skin and cardiac allograft survival in mice
[45].
Effective as a peripheral tolerance induction protocol,
costimulation blockade protocols based on blockade of
the CD40-CD154 pathway have also been used to estab-
lish hematopoietic chimerism leading to the generation
of central tolerance [17–19]. By establishing multilineage
hematopoietic chimerism, these noncytoreductive proto-
cols have proven to promote robust transplantation tol-
erance to a variety of solid-organ allografts across fully
allogeneic barriers when transplanted several weeks after
bone marrow transplantation (BMT) [17, 18] or being
concurrent with BMT [19, 46]. Furthermore, because donor-
reactivity against the host is dependent on the CD40-CD154
pathway [47], costimulation blockade effectively establishes
hematopoietic chimerism in the absence of GVHD [17,
18].
4. VIRUS INFECTION AND
TRANSPLANTATION TOLERANCE
As costimulation blockade protocols move closer to clinical
reality, there is concern that virus infection during toler-
ance induction may (1) induce tolerance to the virus, (2)
prevent the induction or maintenance of tolerance to the
organ allograft, or (3) increase risk to the host. Viruses
are known to stimulate innate immunity by activating
various pattern recognition receptors (PRRs), such as Toll-
like receptors (TLRs) and retinoic acid inducible gene-I-
(RIG-I-) like receptors (RLRs) [48]. Activation of innate
immunity by virus infection leads to the modulation of
adaptive immunity, and it has been shown to impair
transplantation tolerance induction and allograft survival
[49–57].
For example, infection with LCMV before [54], at the
time of [51, 56], or shortly after costimulation blockade for
the induction of peripheral tolerance [57] impairs allograft
survival. Mice treated with costimulation blockade rapidly
reject skin allografts if they are infected with LCMV shortly
after skin transplantation [57]. Interestingly, this effect
appeared to be virus-specific, as infection with vaccinia
virus (VV) and murine cytomegalovirus (MCMV) did not
engender allograft rejection [57]. Furthermore, skin allograft
survival is significantly shortened in LCMV-immune mice
treated with a peripheral tolerance induction protocol con-
sisting of DST and anti-CD154 mAb combination therapies
[54]. Additionally, TLRs and their proinflammatory role in
responding to infection and ischemia are being increasingly
seen as a serious obstacle to solid-organ transplantation [58–
60].
Barriers to the induction of hematopoietic chimerism
and establishment of central tolerance in the setting of
viral infection have also been reported. Anti-CD154 mAb,
CTLA4-Ig, and busulfan treatment fails to induce bone
marrow chimerism and tolerance to skin allografts in the
setting of multiple viral infections [53]. Moreover, using a
nonmyeloablative protocol where anti-CD154 mAb treat-
ment was coupled with sublethal irradiation, Forman et al.
observed that infection with LCMV on the day of BM trans-
plantation not only resulted in allograft rejection but also
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Figure 2: Pathogen recognition systems. The innate immune system senses viral pathogens by recognizing distinct pathogen-associated
molecular patterns (PAMPs) using various pattern recognition receptors (PRRs). Two of the best-characterized virus-sensing PRRs include
member of the Toll-like receptors (TLRs) and retinoic acid inducible gene-I- (RIG-I-) like receptors (RLRs) families. These PRRs couple the
recognition of viral PAMPs to the induction of proinflammatory cytokines through various signaling cascades. The cytosolic RNA helicase
receptors MDA5 and RIG-I initiate the cascade by recruiting the Cardif/TBK1 complex after sensing viral RNA. This activates the kinase
TBK1 to phosphorylate interferon regulatory factor (IRF)-3 and IRF7, resulting in their nuclear translocation and the transcription of
IFNα/β. The cell surface receptor TLR4, in partnership with CD14, couples the recognition of respiratory syncytial virus fusion protein
[78] to cytokine induction by signaling through the MyD88-dependent as well as the MyD88-independent pathways. The endosomal
TLRs, TLR7, TLR8, and TLR9 also signal through MyD88 to activate inflammatory cytokines such as TNF, IL-6, and IFN-α/β. The other
endosomal TLR (TLR3) signals through the MyD88-independent pathway via the TIR domain-containing adaptor molecule TRIF. Via
TRIF, TLR3 signaling can activate NF-kB using TRAF6, and in addition, can induce type I IFN expression probably via TRAF3, TBK1, and
IRF3.
proved lethal to the recipient [55]. Interestingly, conditioned
recipients that were infected and given syngeneic BM grafts
did not die. Recipients of allogeneic BM died by a type
I interferon- (IFN-) dependent mechanism, whereas mice
deficient in the type I IFN receptor survived. The recent
deaths of a cluster of human transplant recipients of LCMV-
infected organs make this finding particularly relevant to the
safety and efficacy of tolerance induction protocols based on
costimulation blockade [61, 62].
5. INNATE IMMUNEACTIVATIONBYVIRUS INFECTION
It has been shown that mice infected with LCMV concurrent
to costimulation blockade treatment [56, 63] or persistently
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Figure 3: Bystander activation of alloreactive T cells by “virus-licensed” APCs. Upon viral infection, detection of pathogen-associated
molecular patterns by PRRs can stimulate the production of inflammatory cytokines such as IFN-α/β, TNF-α, and IL-6. These cytokines
activate alloantigen-processing APCs in a paracrine or autocrine fashion to upregulate MHC classes I and II, as well as costimulatory
molecules, such as CD80 and CD86. The heightened expression of costimulatory molecules elicits the proliferation and differentiation
of alloreactive T cells.
infected with LCMV clone 13 prior to costimulation
blockade treatment [52] rapidly reject skin allografts. In
a transgenic TCR model, LCMV prevents the deletion of
alloreactive CD8+ T cells that is ordinarily induced by
costimulation blockade [56, 63]. In this same model system,
injection of a TLR agonist similarly prevents the deletion of
host alloreactive CD8+ T cells which are required for skin
allograft rejection [64].
Surprisingly, the TLR4 agonist LPS impairs CD8+ T cell
deletion and shortens skin allograft survival by activating
host cells [64] rather than donor cells [64, 65], even though
the transgenic CD8 T cells recognize donor antigen via the
direct pathway. Furthermore, LPS required the expression
of the adaptor molecule myeloid differentiation primary
response gene-88 (MyD88) on the recipient to shorten
allograft survival [65, 66]. These findings are consistent with
clinical data suggesting that TLR4 polymorphisms on the
host, but not the donor, correlate with allograft survival
[67]. Together, these data suggest that TLR activation induces
a soluble mediator that augments host T cell activation,
perhaps through a process of bystander activation (see
below).
Numerous cytokines are reported to be important in
the activation of CD8+ T cells, including IL-12 [29], TNFα
[68, 69], and IFN-α/β [70]. While IL-12 and TNFα are
dispensable for shortened allograft survival induced by LPS
in costimulation blockade treatment protocols [64], IFN-α/β
has been reported to be absolutely essential for LPS to prime
CTLs and induce allograft rejection [65]. Type I IFNs also
proved indispensable for allograft rejection mediated by the
dsRNA mimetic and TLR3 agonist poly I:C [65]. Emerging
data suggest that IFN-α/β can be induced by viruses through
a growing number of pathogen recognition receptor systems
[71–74]. Thus the induction of IFN-α/β by virus infection
or TLR ligation has emerged as an important obstacle to the
establishment of peripheral transplantation tolerance as well
as to the maintenance of self-tolerance [75].
6. SIGNALING PATHWAYS INVOLVED
IN INNATE IMMUNE CELL ACTIVATION
BY VIRUS INFECTION
How does virus-mediated activation of innate immunity lead
to the production of IFN-α/β? At present, the two best-
characterized IFN-α/β-inducing viral recognition systems
are members of the TLR and the retinoic acid inducible
gene-I- (RIG-I-) like receptor (RLR) families (Figure 2).
These receptors are activated by sensing viral nucleic acids
either in the cytosol (RLR) or in endosomes (TLR) of
cells [76]. Cytosolic receptors that detect nucleic acids
upon viral infection are expressed ubiquitously by nucleated
cells, while endosomal receptors, which detect viral particles
that are engulfed from outside rather than from direct
infection, are expressed in specialized cells of the innate
immune system such as macrophages and dendritic cells
[77].
Cytosolic RLRs, exemplified by the proteins RIG-I
and melanoma differentiation factor-5 (MDA5), recognize
double stranded RNA (dsRNA) located in the cytosol
following replication by an RNA virus, or infection by
6 Clinical and Developmental Immunology
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Figure 4: Modulation of regulatory mechanisms by virus infection. Regulatory T cells play a crucial role in transplantation tolerance
to allogeneic organs. Regulatory mechanisms that prevent immune attack on allogeneic tissues may be compromised in the setting of
viral infection by at least two mechanisms. Release of inflammatory cytokines by virus-infected cells can prevent the differentiation of
uncommitted naive CD4+ T cells into Tregs. Naive CD4+ T cells can differentiate into regulatory T cells in the presence of TGF-β. However,
in the presence of TGF-β and proinflammatory cytokines such as IL-6, and perhaps IL-21, naive T cells can be skewed to turn into effector
T cells such as the IL-17-producing TH17 cells. In a separate mechanism, release of cytokines such as IL-6 by infected APCs can render
alloreactive effector cells refractory to suppression by regulatory T cells.
a dsRNA-genome virus, through interaction with their
helicase domains [48]. RLRs contain a caspase recruitment
domain (CARD) [72] which links detection of viral dsRNA
to transcription of IFN-α/β by forming homotypic inter-
actions with the CARD-containing molecule interferon-β
promoter stimulator (IPS-1, also known as mitochondrial
antiviral signaling protein (MAVS), CARD adaptor inducing
IFN-B (CARDIF), and virus-induced signaling adaptor
(VISA)) [79–82]. Activation of IPS-1 triggers members of the
IκB kinase (IKK) family, specifically TANK-binding kinase
1 (TBK-1) and IKKε (also known as inducible IκB kinase,
IKK-i), to phosphorylate and activate interferon regulatory
factory (IRF)-3 and/or IRF7 [83–88]. Once activated, IRF3
and IRF7 translocate to the nucleus and bind to interferon-
stimulated response elements (ISREs) to induce the expres-
sion of IFN-α and IFN-β, as well as other IFN-inducible
genes [48, 89, 90].
It has recently been recognized that cytoplasmic sensing
of DNA can also trigger IFN-α and IFN-β production [91–
93]. This pathway is thought to intersect with the RIG-
I and MDA5 pathways at the level of TBK-1 and IKK-
I [91], and it requires IRF3 for IFN-α/β induction [92].
A candidate cytosolic recognition receptor that senses and
is activated by DNA has been described [94]. This recep-
tor, known as DNA-dependent activator of IFN-regulatory
factors (DAI), was reported to induce type I IFN upon
recognition of bacterial and mammalian as well as viral
DNAs [94].
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Figure 5: Heterologous immunity; cross-reactivity between viral and allogeneic antigens. Unlike the very small proportion of naive T cells that
can respond to any given pathogen (reported to be ∼1:200 000), the frequency of T cells that directly recognize allogeneic antigens, such as
MHC, is thought to be within 1:100–1:10. A proportion of those TCRs that recognize alloantigens, therefore, may have arisen as a result of
virus infection that induces virus-specific T cells that cross-react with allo-MHC. Activation of these T cells may result in the recognition of
MHC molecules found on donor tissues, such as the endothelium of transplanted organs, precipitating allograft rejection.
With the exception of TLR4, all known TLRs that
induce type I IFN recognize nucleic acids, and are found in
the endosomal compartment of cells. These include TLR3,
TLR7, TLR8, and TLR9. Unlike the cytoplasmic nucleic acid
receptors, the cellular distribution of endosomal TLRs is
much more restricted. TLR7 and TLR9, which recognize
ssRNA [95, 96] and unmethylated DNA that contain CpG
motifs [97], respectively, are expressed highly on both
conventional (cDC) and plasmacytoid (pDC) dendritic cells.
However, they can also be expressed on other hematopoietic
cells, including B cells [98, 99]. TLR3, which recognizes
dsRNA [71], has a broader distribution than TLR7 and
TLR9, and can be found on nonhematopoietic cells such as
astrocytes and epithelial cells of the cervix, airway, uterus,
vagina, intestine, and cornea [76, 98–100]. Its expression,
however, is thought to be highest in cDCs [76, 100].
Similar to the other non-IFN-α/β-inducing TLRs, TLR3,
7, 8, and 9 are capable of activating both NF-κB and
MAPK cascades and triggering the transcription of scores of
proinflammatory cytokines and chemokines [76, 99, 100].
However, the endosomal TLRs are also capable of signaling
through additional cascades, which results in the expression
of type I IFNs. Recognition of dsRNA by TLR3 results in
the activation of the adaptor molecule Toll/interleukin-1
receptor (TIR) domain-containing adaptor protein inducing
IFN-β (TRIF) [101]. TRIF interacts with tumor necrosis
factor receptor-associated factor (TRAF)-3 to activate TBK1
[88] and, as described above, leads to the activation of
IRF3 and IRF7 and induction of type I IFN. In contrast,
the coupling of TLR7 and TLR9 to IFN-α/β production
involves the adaptor molecule MyD88 [97, 102]. Following
recognition of either ssRNA or unmethylated DNA, a
large complex consisting of MyD88, TRAF3, TRAF6, IL-1
receptor-associated kinase (IRAK)-4, IRAK-1, IKK-α, and
IRF-7 is recruited to the TLR [48, 87, 88, 103–105]. Following
recruitment of the complex, cytokines downstream of NF-
κB are stimulated, and type I IFN expression is induced in
an osteopontin (OPN) [106] and IRF7-dependent fashion
[48, 89]. Interestingly, stimulation of TLR7 and TLR9 in
cDCs is capable of inducing the expression of cytokines that
are downstream of the NF-κB pathway, such as IL-6 and
IL-12. However, only pDCs are capable of producing IFN-
α in response to ssRNA and CpG-containing DNA [76]. As
exemplified by the multitude of signaling pathways by which
TLRs can activate innate immunity, it is clear that virus
or microbial infection has multiple ways to active innate
8 Clinical and Developmental Immunology
immunity and modulate the adaptive immune system during
tolerance induction.
7. MECHANISMS OF VIRUS-MEDIATED MODULATION
OF TRANSPLANTATION TOLERANCE
There are multiple mechanisms by which virus infection or
TLR agonists may modulate tolerance induction and allo-
graft survival. We will focus on three potential mechanisms.
First, virus infection can mature APCs to prime non-cross-
reactive T cells, a process called bystander activation [107,
108]. Second, virus infection may stimulate innate immune
cells to produce cytokines that suppress tolerance-promoting
regulatory T cells [109]. Third, virus infection may lead to
the generation of virus-specific T cells that can cross-react
with alloantigens, a phenomenon known as heterologous
immunity [110].
7.1. Bystander activation
A mechanism by which virus infection may modulate
tolerance induction is through bystander activation. As
described above, virus infection activates innate immunity,
and is able to mature APCs to “license” them to activate
non-cross-reactive T cells. CD4+ T cells are known to
play a pivotal role in the licensing of antigen-presenting
cells (APCs) [111]. The intercourse between antigen-specific
CD4+ T cells and antigen-presenting APCs is thought to
be crucial for the generation of a full immune response.
In the setting of viral infection, virus-specific CD4+ T
cells facilitate the maturation of virus-presenting APCs
via CD154-CD40 interactions. Consequently, the APC is
stimulated to upregulate costimulatory molecules, as well
as to secrete proinflammatory cytokines. These molecules
then feed back on the T cell, stimulate it to become fully
activated, and release additional inflammatory cytokines and
growth factors. Allospecific T cells that have encountered
cognate alloantigen can be activated in this inflammatory
milieu even if they do not cross-react with viral antigens. This
process is traditionally referred to as bystander activation
[111].
Viruses have also been shown to mature APCs indepen-
dently of the normally required CD154-CD40 interaction.
LCMV infection stimulates the upregulation of MHC classes
I and II, CD40, CD80, and CD86 in the presence of CTLA-
4-Ig and anti-CD154 mAb [51]. The molecular mechanisms
that govern this process have not been fully elucidated;
however, the induction of type I IFNs by virus-infected
APCs is a likely candidate. IFN-α/β is known to directly
induce the maturation of immature DCs, and it results
in the upregulation of MHC and costimulatory molecules
[112, 113]. Given that pDCs can produce up to a thousand-
fold more type I IFN than other cells [113, 114], we propose
that viral detection by pDCs triggers the release of IFN-
α/β that can in turn act in a paracrine or autocrine fashion
to mature alloantigen-presenting APCs (Figure 3). Thus,
these “IFN-α/β-licensed” alloantigen-presenting APCs could
directly stimulate alloreactive T cells, even in the presence of
costimulation blockade.
7.2. Regulatory cell suppression
The induction and maintenance of CD4+ regulatory T cells
(Tregs) are essential to allograft survival [115–117]. There-
fore, a second mechanism by which viruses could impair
tolerance induction is through modulation of the generation
or activity of this important T cell subset. In addition to
priming cells through an IFN-α/β-dependent mechanism,
TLR activation also prevents the intragraft recruitment of
regulatory T cells in an MyD88-dependent manner [66]. This
observation extended earlier work showing that the MyD88
pathway plays an important role in the rejection of minor
antigens [118] and cardiac allografts [119].
IL-6 is an MyD88-dependent cytokine that has emerged
as a candidate mediator for impairing regulatory T cell
generation and function; its production is diminished in
untreated [119]—as well as LCMV-infected [120]—mice
deficient in MyD88. CD4+ T cells develop a FoxP3+ regula-
tory T cell phenotype when they are activated in the presence
of TGF-β. However, when CD4+ T cells are activated in
the presence of TGF-β and IL-6, this regulatory phenotype
is suppressed and the cells develop a proinflammatory
TH17 cell phenotype [121] (Figure 4). Therefore, virus
infection may precipitate allograft rejection by preventing
the generation of Tregs following costimulation blockade and
instead favor development of proinflammatory effector T
cells.
IL-6 has also been shown to be important in regulating
antigen-specific adaptive immune responses via additional
mechanisms. Pasare et al. demonstrated that microbial
induction of the TLR pathway on DCs enabled effector T
cells to overcome suppression by CD4+CD25+ regulatory
cells [122] (Figure 4). They reported that secretion of
soluble mediators (principally IL-6) by TLR-activated DCs
could render effector T cells refractory to Treg-mediated
regulation, permitting activation of antigen-specific T cells in
the presence of regulatory T cells. Hence, virus infection may
trigger allograft rejection by compromising key regulatory
mechanisms such as preventing the generation of regulatory
T cells by costimulation blockade as well as by enabling
alloreactive T cells to escape Treg-mediated suppression.
7.3. Heterologous immunity
The classic view of clonal T cell activation is that one
TCR interacts with one cognate antigen. However, we
now understand that TCR binding is degenerate, and can
recognize multiple related and unrelated antigens. The
ability of an antigen-specific T cell to cross-react with
multiple antigens, known as heterologous immunity [110],
can influence immunodominance, protective immunity, and
immunopathology during subsequent viral infections [110,
123, 124].
In studies of peripheral tolerance induction, of particular
interest to transplant scientists is the observation that virus-
specific T cells cross-react with alloantigens (Figure 5) [125,
126]. Yang et al. have reported that acute infection with
VV, MCMV, or arena viruses LCMV and pichinde virus
(PV) resulted in the spontaneous generation of cytotoxic
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lymphocytes (CTLs) with cytolytic activity towards allo-
geneic cells [127, 128]. These results were further supported
by Nahill and Welsh [126], who used limiting dilution
analyses to demonstrate that T cell clones specific for
virus-infected syngeneic cells also kill uninfected allogeneic
targets. Our report using virus-specific tetramers and an
intracellular cytokine assay confirmed the findings that
LCMV infection led to the generation of virus-specific CD8
T cells that cross-react with alloantigens, and further showed
that virus-immune mice were refractory to the induction
of tolerance by costimulation blockade [57]. Others have
also reported that virus-immune mice are refractory to
tolerance induction by costimulation blockade [53]. Because
memory T cells are resistant to the induction of tolerance
by costimulation blockade [107, 108], our data suggest that
the allo-cross-reactive virus-specific memory T cells may
precipitate the rejection of allografts even in the presence of
costimulation blockade.
8. VIRUS INFECTION AND ESTABLISHED
ALLOGRAFT SURVIVAL
Surprisingly, mice infected with LCMV one day after trans-
plantation also exhibit shortened allograft survival [57].
Interestingly, the longer time after transplantation is, the
less impact LCMV infection has on allograft survival. The
deletion of alloreactive CD8+ T cells is thought to be
complete at this time [41, 42], making it improbable that
LCMV is interfering with deletion. However, because cos-
timulation blockade protocols are only implemented during
the peritransplant period, it is possible that LCMV infection
shortly after transplantation prevents the generation of
regulatory T cells, which have been shown to require up
to 30 days after costimulation blockade to develop [129].
Further research is necessary to elucidate the mechanisms
by which LCMV shortens allograft survival during the post-
transplantation timeframe.
9. SUMMARY
Viral infection presents a potent barrier to the induction of
transplantation tolerance. In this review, we have discussed
potential mechanisms by which viral infection modulates
organ allograft survival in the setting of transplantation
tolerance. We have briefly summarized data on three mech-
anisms by which viral infection may mediate these effects:
bystander activation, modulation of Tregs, or heterologous
immunity. Recognition of viruses by pattern recognition
receptors on innate immune cells can also directly stimulate
the maturation of APCs, and thus may lead to bystander
activation and licensing of alloreactive T cells. Activation of
APCs by viruses may trigger the release of cytokines such
as IL-6 that can prevent the generation and/or function of
regulatory T cells that are essential for transplantation toler-
ance. Finally, heterologous immunity may be responsible for
the discrepancy that has been encountered when tolerance
strategies that work in specific pathogen-free rodent models
fail when translated to nonhuman primates and to humans
[130], which have been exposed to a variety of pathogens
and thus have large memory T cell pools. Understanding
the cellular and molecular mechanisms by which viruses
and other microbial organisms modulate transplantation
tolerance may lead to novel approaches that improve the
efficacy of allogeneic organ transplantation.
ABBREVIATIONS
APC: Antigen presenting cell
BMT: Bone marrow transplantation
CARD: Caspase recruitment domain
CARDIF: CARD adaptor inducing IFN-B
cDC: Conventional dendritic cell
CTL: Cytotoxic T lymphocytes
DC: Dendritic cell
DAI: DNA-dependent activator of IFN-regulatory
factors
dsRNA: Double stranded RNA
DST: Donor-specific transfusion
GP: Glycoprotein
GVHD: Graft-versus-host disease
IFN: Interferon
IKK: IκB kinase
IKK-I: Inducible IκB kinase
IPS-1: Interferon-β promoter stimulator
IRAK: IL-1 receptor-associated kinase
IRF: Interferon regulatory factory
ISRE: Interferon-stimulated response element
LCMV: Lymphocytic choriomeningitis virus
mAb: Monoclonal antibody
MAVS: Mitochondrial antiviral signaling protein
MDA5: Melanoma differentiation factor-5
MCMV: Murine cytomegalovirus
MyD88: Myeloid differentiation primary response
gene-88
NP: Nucleoprotein
OPN: Osteopontin
PRR: Pattern recognition receptor
PV: Pichinde virus
RIG-I: Retinoic acid inducible gene I
RLR: RIG-I-like receptor
pDC: Plasmacytoid dendritic cell
TBK-1: TANK-binding kinase 1
TCR: T cell receptor
TIR: Toll/interleukin-1 receptor
TLR: Toll-line receptor
TRAF: Tumor necrosis factor receptor-associated
factor
Treg: Regulatory T cell
TRIF: TIR-domain-containing adaptor protein
inducing IFN-β
VISA: Virus-induced signaling adaptor
VV: Vaccinia virus
WBI: Whole-body irradiation
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